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Early detection and proper care of breast cancer are currently the best available approaches to the treatment of
patients with the disease. In countries with a breast cancer screening programme, there has been a demonstrated
reduction in breast cancer-related mortality. Such reduction has also been observed in Switzerland, a country in
which no national programme of screening is available. Although there is no doubt that early diagnosis might
have had a major role in reducing breast cancer mortality the magnitude of this effect is unknown. Research with
tailored approaches on alternative imaging for early detection of breast cancer in high-risk women and on treat-
ments offered according to proper criteria of responsiveness to therapies is warranted.
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Increased attention has been given to breast cancer mainly as a
result of the strong emotional attitude towards the breast, the shift-
ing of paradigms related to understanding the disease, and develop-
ments of preventive, diagnostic and therapeutic modalities. Advances
in each of these three latter domains have a potential impact upon
freedom from disease and, ultimately, upon survival. Early diag-
nosis by means of mammographic screening for breast cancer has
been implemented in many countries and there is definitive infor-
mation on the reduction in breast cancer mortality in several
nations, worldwide. Uncertainty exists, however, concerning the
relative importance of prevention, screening and treatment that
have contributed to this progress. Clarifying this issue might be
useful for strategic decisions concerning the distribution of
resources for further progress.
There is little doubt that delayed diagnosis of asymptomatic
breast carcinoma (e.g. by 6–12 months) is associated with pro-
gression of breast cancer [1]. It is, therefore, reasonable to assume
that any survival benefit associated with early diagnosis of breast
cancer might be partially due to the better treatment outcome of
less advanced disease.
In addition to early diagnosis, the features that potentially influ-
ence overall survival include the following: proper and timely sur-
gical treatment, completion of local (and regional) treatment with
radiation therapy, properly tailored systemic adjuvant therapy
and, following relapse, proper systemic therapy to control symp-
toms and disease progression.
To assess the evidence for breast cancer mortality reduction and
efficacy of systemic treatments to control disease progression, we
consider separately the adjuvant setting (breast cancer confined to
the breast and the ipsilateral axillary lymph nodes; treatment aimed
at avoiding overt metastatic disease) and the advanced disease
setting. Adjuvant systemic therapy is given with a curative intent,
while treatment for advanced disease is typically tailored to con-
trol disease progression and ameliorate symptoms of disease.
There is overwhelming evidence that adjuvant systemic therapies
reduce the risk of relapse and improve overall survival based on
results from randomised clinical trials. Treatments such as tamoxifen
{given for 5 years, mainly for women with estrogen receptor-
expressing breast cancer [2], ovarian ablation [3] and poly-
chemotherapy (given for 3–6 months) [4]} are very effective,
especially for properly selected patient populations, while immune
therapy [5] is not effective.
Similarly, in the advanced disease setting, several first-line
systemic therapies showed an overall survival benefit in favour of
one treatment or the other (novel endocrine agents, newer chemo-
therapy regimens versus older ones, monoclonal antibodies). The
magnitude of treatment effects to prolong overall survival is
unknown because several therapies given to control symptoms
are also very effective for controlling disease progression. Two
randomised trials have been conducted to ascertain whether first-
line treatment for overt metastases should include the simul-
taneous use of available treatment modalities, or whether the
sequential use of potentially effective treatments might be prefer-
able to prolong time to disease progression and improve overall
survival. Both trials indicated that for patients with potentially
endocrine-responsive disease the sequential use of endocrine
therapy followed by chemotherapy was the more efficient strategy
as compared to the simultaneous use of chemotherapy and endo-
crine therapy as first therapeutic approach [6, 7]. These trials also
showed that chemotherapy should be part of the initial therapeutic
approach for patients who had a rapidly growing disease, or, obvi-
ously, those who had endocrine nonresponsive metastases. Thus,
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it is likely that more effective therapies for women with advanced
disease, especially if chosen with reasonable criteria for providing
the longest progression-free survival, are presumably responsible
for some of the breast cancer specific mortality reduction seen in
recent years [8].
Given the demonstrated effect of systemic treatments to reduce
breast cancer specific mortality, it is important to consider disease-
and patient-related features to develop hypotheses regarding the
choice of systemic therapy to improve breast cancer survival.
Improved imaging of breast cancer and screening programmes
increased the number of small breast tumours detected [9]. Further-
more, asymptomatic breast cancer, mainly detected during screen-
ing, is considered to be biologically less aggressive [10, 11]. It
might be hypothesised that proper and timely local and systemic
treatments might be easier to complete for less aggressive tumours
and have a larger chance of being successful in terms of accept-
ance, control of disease and reduced breast cancer mortality.
Some countries, such as the UK, have activated mammography
screening programmes since 1988 for women aged 50–64 years
[12]. Other countries, such as the USA, have also advertised
a strict adherence to yearly mammograms, starting for women
>40 years of age [13]. In Switzerland (CH) there is no systematic
screening for breast cancer [14], but the country has a high density
of physicians, especially gynaecologists, who traditionally offer
care and secondary prevention for women’s malignancies and
advertise for yearly check-ups. Considering the last decade, the
number of women in Switzerland having had a mammography in
the previous 2 years was about one-third compared to USA and
UK figures [15, 16]. The reduction in breast cancer mortality for
women overall, and for women of premenopausal age, for whom
the issue of intensity of screening and of asymptomatic detection
of breast cancer is less relevant, was similar. Table 1 provides
information on the breast cancer mortality national statistics for
the UK, USA and Switzerland. While there may be limitations due
to differences in case ascertainment methodologies, such cross-
national statistics are routinely presented either together in the
same table or separately in different tables. All three countries
reflect similar reductions in breast cancer mortality over time.
Evidence on the role of systemic adjuvant therapies for prolong-
ing survival is based upon several clinical trials. Particularly for
premenopausal patients, the magnitude of the effect of adjuvant
therapies is large. In general, premenopausal age groups do not
undergo screening mammography and increased early diagnosis
might not be attributed to screening, but rather to increased aware-
ness of women to the disease, improved imaging modalities and
changes in the characteristics of the disease (e.g. increased inci-
dence of ductal carcinoma in situ). Among young women, the fact
that reduction in breast cancer mortality is substantial for the cohorts
35–49 years old (Table 1) may be related to the recent finding
derived from several randomised trials of efficacy of adjuvant
therapies according to patient age [17]. The trials confirmed that
the effect of chemotherapy for premenopausal patients is substan-
tial, but the analysis also led to the observation that very young
women (i.e. <35 years old) with endocrine-responsive tumours
had a statistically significantly higher risk of relapse than older
premenopausal patients with such tumours despite receiving a
similar cytotoxic treatment. This observation, based on 11285
patients, contradicts the empirical assumption that more intensive
chemotherapy should be given to younger women based on the
dogma that higher risk of relapse represents by itself an indication
for adjuvant chemotherapy [18]. A tailored adjuvant systemic
treatment selected according to the biological features of the dis-
ease provides improved results. In fact, in contrast to the patients
with endocrine responsive disease, the analysis of treatment out-
come for patients with endocrine nonresponsive breast cancer
who received chemotherapy showed similar results for younger
and older premenopausal women [17].
There is no doubt that early diagnosis might play a major role in
reducing breast cancer mortality. The magnitude of this effect is
unknown. Despite the observed reduction in breast cancer mortal-
ity based on national statistics, there is still much room for further
substantial improvement. A better understanding of responsive-
Table 1. Breast cancer mortality (females; standardized death rate on European population) for countries with an extended national screening programme 
(UK), strong national cancer society and community-based screening programmes (USA) and very limited screening programme (Switzerland, CH)
Per cent reduction compared with baseline for 1988. The reduction in mortality between 1988 and 1999 provides the most updated figures for the UK and 
Switzerland. Additional information on the time interval between 1988 and 1998 is provided for the UK, Switzerland and the USA. Although differences in 
case ascertainment methodologies limit direct comparisons, all three countries reflect similar reductions in breast cancer mortality over time.
Country All ages 35–49 years <35 years
1988 mortality/
100 000 women
% Reduction within 
the time period
1988 mortality/
100 000 women
% Reduction within 
the time period
1988 mortality/
100 000 women
% Reduction within 
the time period
UK
1988–98 41 –20.9 32 –25.3 1.2 –31.2
1988–99 –23.1 –29.0 –22.3
USA
1988–98 32 –17.4 24 –23.7 0.9 –19.5
Switzerland (CH)
1988–98 37 –26.4 25 –25.4 0.7 –11.9
1988–99 –33.5 –41.0 +7.5
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ness to treatments will help to better tailor therapies even for
asymptomatic breast cancers.
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